China Meheco Group Co., Ltd.

Equities

600056

CNE000000Q29

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
10.98 CNY +0.73% Intraday chart for China Meheco Group Co., Ltd. -1.79% -1.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Meheco's Unit Gets Nod to Raise Specifications for Piperacillin Sodium for Injection MT
Argatroban Injection of Meheco's Subsidiary Passes Chinese Drug Regulator's Evaluation MT
Meheco's Unit Gets Nod to Market Peramivir Injection; Shares Down 4% MT
Meheco Unit's Antibiotic Passes Regulatory Evaluation in China MT
China Meheco Group Co., Ltd. agreed to acquire 46% stake in Hainan General Kangli Pharmaceutical Co., Ltd. from General Technology Group Pharmaceutical Holding, Ltd. for CNY 190 million. CI
Genertec Universal, Parent Form 2 Billion Yuan Fund MT
China Meheco’s Hypertension Drug Passes Generic Consistency Evaluation MT
China Meheco Group's Drugs Chosen for China's Centralized Drug Procurement MT
China Meheco Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China Meheco Group Unit's Norfloxacin Capsules Passes Drug Regulator's Evaluation MT
China Meheco’s Antibiotic Passes Generic Consistency Evaluation MT
China Meheco Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Medicine Health Industry Gets Registration Certificate for Sitafloxacin Tablets MT
China Meheco Group Co., Ltd.(SHSE:600056) added to Shanghai Stock Exchange 180 Value Index CI
China Meheco Group Co., Ltd.(SHSE:600056) added to SSE 180 Index CI
New rules to dampen Chinese interest to list in Europe, say bankers RE
China Meheco Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
China Meheco Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China Medicine Health Industry Unit Gets Regulatory Nod for Gastrointestinal Bleeding Drug MT
China Medicine Health Industry Unit's Injection Passes Regulator's Consistency Evaluation MT
China Meheco’s Generic Azithromycin Passes Consistency Test MT
China Meheco Rents Office Property for 57 Million Yuan MT
Meheco Unit's Anti-Bacterial Injection Passes Regulator's Evaluation MT
Paxlovid sales forecasts may change with Pfizer view on China RE
AstraZeneca signs COVID treatment deal with China's Genertec Meheco RE
Chart China Meheco Group Co., Ltd.
More charts
China Meheco Group Co., Ltd. is mainly engaged in the operation of industrial pharmaceutical, commercial pharmaceutical and international trading businesses. Industrial Pharmaceutical segment mainly involves in the manufacture and distribution of chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, herbal decoction pieces and other pharmaceutical products. Commercial Pharmaceutical segment is mainly engaged in the wholesale and distribution of pharmaceuticals and medical devices. Trading segment is mainly engaged in the international exporting business and medical resourcing introduction.
More about the company
  1. Stock Market
  2. Equities
  3. 600056 Stock
  4. News China Meheco Group Co., Ltd.
  5. Argatroban Injection of Meheco's Subsidiary Passes Chinese Drug Regulator's Evaluation